Rehabilitating a brain with Alzheimer's: A proposal

Clinical Interventions in Aging

Volumn 6, Issue 1, 2011, Pages 53-59

  Aranda Abreu, Gonzalo Emiliano ^a,b   Hernández Aguilar, María Elena ^a,b   Denes, Jorge Manzo ^a,b   Hernández, Luis Isauro García ^a,b   Rivero, Marisol Herrera ^a  

^a UNIVERSIDAD VERACRUZANA   (Mexico)

^b Universidad Veracruzana ^*  (Mexico)

Author keywords

Alzheimer; Drugs; Rehabilitation

Indexed keywords

CATECHIN; DONEPEZIL; FOLIC ACID; GALANTAMINE; GINKGO BILOBA EXTRACT; MEMANTINE; NIMESULIDE; OMEGA 3 FATTY ACID; RESVERATROL; RIVASTIGMINE; TACRINE; NOOTROPIC AGENT; VITAMIN;

ALZHEIMER DISEASE; BRAIN DAMAGE; CONCENTRATION RESPONSE; DRUG EFFECT; DRUG MECHANISM; HUMAN; LIVER TOXICITY; NERVE CELL MEMBRANE; NERVE CELL PLASTICITY; NERVE REGENERATION; NEUROPROTECTION; NONHUMAN; REVIEW; REYE SYNDROME; UNSPECIFIED SIDE EFFECT; AGED; CASE REPORT; CHILD; FEMALE; NERVE DEGENERATION; PHYTOTHERAPY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHILD; FEMALE; HUMANS; NERVE DEGENERATION; NOOTROPIC AGENTS; PHYTOTHERAPY; VITAMINS;

EID: 80051646406     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/CIA.S14008     Document Type: Review

References (52)

1. Perez-Tur J. Genetics and Alzheimer's disease. Rev Neurol. 2000;30:161-169.
2. Lopez de Munain A. Classification of mitochondrial diseases. Rev Neurol. 1998;26 Suppl 1:S9-S14.
3. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci. 1991;12:383-388.
4. Jarrett JT, Lansbury PTJ. Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? Cell. 1993;73:1055-1058.
5. Hu X, Hicks CW, He W, et al. BACE1 modulates myelination in the central and peripheral nervous system. Nat Neurosci. 2006;9:1520-1525.
6. Willem M, Lammich S, Haass C. Function, regulation and therapeutic properties of beta-secretase (BACE1). Semin Cell Dev Biol. 2009;20:175-182.
7. Nguyen V, Hawkins C, Bergeron C, et al. Loss of nicastrin elicits an apoptotic phenotype in mouse embryos. Brain Res. 2006;1086:76-84.
8. Gauthier S, Scheltens P. Can we do better in developing new drugs for Alzheimer's disease? Alzheimers Dement. 2009;5:489-491.
9. Qizilbash N, Birks J, Lopez Arrieta J, Lewington S, Szeto S. WITHDRAWN: Tacrine for Alzheimer's disease. Cochrane Database Syst Rev. 2007:CD000202.
10. Alfirevic A, Mills T, Carr D, et al. Tacrine-induced liver damage: An analysis of 19 candidate genes. Pharmacogenet Genomics. 2007;17:1091-1100.
11. Tsuno N. Donepezil in the treatment of patients with Alzheimer's disease. Expert Rev Neurother. 2009;9:591-598.
12. Winblad B. Donepezil in severe Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2009;24:185-192.
13. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE. Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev. 2009:CD001191.
14. Annicchiarico R, Federici A, Pettenati C, Caltagirone C. Rivastigmine in Alzheimer's disease: Cognitive function and quality of life. Ther Clin Risk Manag. 2007;3:1113-1123.
15. Matharu B, Gibson G, Parsons R, et al. Galantamine inhibits betaamyloid aggregation and cytotoxicity. J Neurol Sci. 2009;280:49-58.
16. Melo JB, Sousa C, Garcao P, Oliveira CR, Agostinho P. Galantamine protects against oxidative stress induced by amyloid-beta peptide in cortical neurons. Eur J Neurosci. 2009;29:455-464.
17. Martinez-Coria H, Green KN, Billings LM, et al. Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol. 2010;176:870-880.
18. Aranda-Abreu GE, Behar L, Chung S, Furneaux H, Ginzburg I. Embryonic lethal abnormal vision-like RNA-binding proteins regulate neurite outgrowth and tau expression in PC12 cells. J Neurosci. 1999;19:6907-6917.
19. Aronov S, Aranda G, Behar L, Ginzburg I. Axonal tau mRNA localization coincides with tau protein in living neuronal cells and depends on axonal targeting signal. J Neurosci. 2001;21:6577-6587.
20. Dubey M, Chaudhury P, Kabiru H, Shea TB. Tau inhibits anterograde axonal transport and perturbs stability in growing axonal neurites in part by displacing kinesin cargo: Neurofilaments attenuate tau-mediated neurite instability. Cell Motil Cytoskeleton. 2008;65:89-99.
21. Lippens G, Sillen A, Landrieu I, et al. Tau aggregation in Alzheimer's disease: What role for phosphorylation? Prion. 2007;1:21-25.
22. Relton JK, Strijbos PJ, Cooper AL, Rothwell NJ. Dietary N-3 fatty acids inhibit ischaemic and excitotoxic brain damage in the rat. Brain Res Bull. 1993;32:223-226.
23. Fan YY, McMurray DN, Ly LH, Chapkin RS. Dietary (n-3) polyunsaturated fatty acids remodel mouse T-cell lipid rafts. J Nutr. 2003;133:1913-1920.
24. Beltz BS, Tlusty MF, Benton JL, Sandeman DC. Omega-3 fatty acids upregulate adult neurogenesis. Neurosci Lett. 2007;415:154-158.
25. Hering H, Lin CC, Sheng M. Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J Neurosci. 2003;23:3262-3271.
26. Hou Q, Huang Y, Amato S, Snyder SH, Huganir RL, Man HY. Regulation of AMPA receptor localization in lipid rafts. Mol Cell Neurosci. 2008;38:213-223.
27. Stetzkowski-Marden F, Recouvreur M, Camus G, Cartaud A, Marchand S, Cartaud J. Rafts are required for acetylcholine receptor clustering. J Mol Neurosci. 2006;30:37-38.
28. Clement AB, Gimpl G, Behl C. Oxidative stress resistance in hippocampal cells is associated with altered membrane fluidity and enhanced nonamyloidogenic cleavage of endogenous amyloid precursor protein. Free Radic Biol Med. 2010;48:1236-1241.
29. Ma QL, Yang F, Rosario ER, et al. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci. 2009;29:9078-9089.
30. Amtul Z, Uhrig M, Rozmahel RF, Beyreuther K. Structural basis for the differential effects of omega-3 and omega-6 fatty acids on Abeta production and amyloid plaques. J Biol Chem. 2010 Oct 22. [Epub ahead of print].
31. Wang JW, David DJ, Monckton JE, Battaglia F, Hen R. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci. 2008;28:1374-1384.
32. Lucas G, Du J, Romeas T, et al. Selective serotonin reuptake inhibitors potentiate the rapid antidepressant-like effects of serotonin4 receptor agonists in the rat. PLoS One. 2010;5:e9253.
33. Kronenberg G, Colla M, Endres M. Folic acid, neurodegenerative and neuropsychiatric disease. Curr Mol Med. 2009;9:315-323.
34. Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer's disease. Arch Neurol. 1998;55:1409-1415.
35. Bastianetto S, Zheng WH, Quirion R. The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide-induced toxicity: Involvement of its flavonoid constituents and protein kinase C. J Neurochem. 2000;74:2268-2277.
36. Grundman M, Grundman M, Delaney P. Antioxidant strategies for Alzheimer's disease. Proc Nutr Soc. 2002;61:191-202.
37. Drieu K. Preparation and definition of Ginkgo biloba extract. Presse Med. 1986;15:1455-1457.
38. Yao Z, Drieu K, Papadopoulos V. The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloid-induced cell death by inhibiting the formation of beta-amyloid-derived diffusible neurotoxic ligands. Brain Res. 2001;889:181-190.
39. Longpre F, Garneau P, Christen Y, Ramassamy C. Protection by EGb 761 against beta-amyloid-induced neurotoxicity: Involvement of NF-kappaB, SIRT1, and MAPKs pathways and inhibition of amyloid fibril formation. Free Radic Biol Med. 2006;41:1781-1794.
40. Sovak M. Grape extract, resveratrol, and its analogs: A review. J Med Food. 2001;4:93-105.
41. Conte A, Pellegrini S, Tagliazucchi D. Synergistic protection of PC12 cells from beta-amyloid toxicity by resveratrol and catechin. Brain Res Bull. 2003;62:29-38.
42. Rossi L, Mazzitelli S, Arciello M, Capo CR, Rotilio G. Benefits from dietary polyphenols for brain aging and Alzheimer's disease. Neurochem Res. 2008;33:2390-2400.
43. Scali C, Prosperi C, Vannucchi MG, Pepeu G, Casamenti F. Brain inflammatory reaction in an animal model of neuronal degeneration and its modulation by an anti-inflammatory drug: Implication in Alzheimer's disease. Eur J Neurosci. 2000;12:1900-1912.
44. Candelario-Jalil E, Alvarez D, Gonzalez-Falcon A, et al. Neuroprotective efficacy of nimesulide against hippocampal neuronal damage following transient forebrain ischemia. Eur J Pharmacol. 2002;453:189-195.
45. Daubert EA, Condron BG. Serotonin: A regulator of neuronal morphology and circuitry. Trends Neurosci. 2010;33:424-434.
46. Altman HJ, Stone WS, Ogren SO. Evidence for a possible functional interaction between serotonergic and cholinergic mechanisms in memory retrieval. Behav Neural Biol. 1987;48:49-62.
47. Buhot MC, Martin S, Segu L. Role of serotonin in memory impairment. Ann Med. 2000;32:210-221.
48. Dougherty JJ, Nichols RA. Cross-regulation between colocalized nicotinic acetylcholine and 5-HT3 serotonin receptors on presynaptic nerve terminals. Acta Pharmacol Sin. 2009;30:788-794.
49. National Institutes of Health. Alzheimer's Disease Medications. 2008. Available from: http://www.nia.nih.gov/Alzheimers/Publications/medicationsfs.htm. Accessed on January 18, 2010.
50. Stix G. Turbocharging the brain. Sci Am. 2009;301:46-49.
51. Jha AM, Abha. Assessment of cytotoxic and clastogenic effects of nimesulide: An NSAID drug in somatic cells of BALB/c mice in vivo. Drug Chem Toxicol. 2010;33:204-208.
52. Goncalves MB, Williams EJ, Yip P, Yanez-Munoz RJ, Williams G, Doherty P. The COX-2 inhibitors, meloxicam and nimesulide, suppress neurogenesis in the adult mouse brain. Br J Pharmacol. 2010;159:1118-1125.